Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Status:
Terminated
Trial end date:
2021-04-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus
pembrolizumab or pemigatinib alone versus the standard of care for participants with
metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin,
are harboring FGFR3 mutation or rearrangement, and who have not received prior treatment.